A similar study by Miller et al. using low dose IL-2 after autologous HSCT in patients with lymphoma and breast cancer also demonstrated a more than 10-fold increase in PB NK cells with enhanced cytotoxicity against resistant cell lines [35]. Here, IL2 is linked to lymphoma.